Nanjing Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NANJING
NANJING has five approved drugs.
There is one US patent protecting NANJING drugs.
There are nine patent family members on NANJING drugs in five countries and eleven supplementary protection certificates in eight countries.
Summary for Nanjing
| International Patents: | 9 |
| US Patents: | 1 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Nanjing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanjing King Friend | LIRAGLUTIDE | liraglutide | SOLUTION;SUBCUTANEOUS | 218115-001 | Apr 2, 2025 | AP1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nanjing Delova | QAMZOVA | meloxicam | SOLUTION;INTRAVENOUS | 217593-001 | Apr 22, 2025 | RX | Yes | Yes | 12,059,423 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Nanjing King Friend | NICARDIPINE HYDROCHLORIDE | nicardipine hydrochloride | INJECTABLE;INJECTION | 216819-001 | Aug 20, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nanjing King Friend | PROPOFOL | propofol | INJECTABLE;INJECTION | 217945-001 | Dec 2, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nanjing Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3777862 | ⤷ Start Trial |
| China | 116327960 | ⤷ Start Trial |
| South Korea | 102843054 | ⤷ Start Trial |
| South Korea | 20210007951 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Nanjing Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2209800 | 122014000114 | Germany | ⤷ Start Trial | PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918 |
| 2209800 | 14C0085 | France | ⤷ Start Trial | PRODUCT NAME: LIRAGLUTIDE ET INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/14/947 20140918 |
| 2209800 | 132014902311502 | Italy | ⤷ Start Trial | PRODUCT NAME: INSULINA DEGLUDEC/LIRAGLUTIDE(XULTOPHY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/947, 20140918 |
| 2488169 | C202330042 | Spain | ⤷ Start Trial | PRODUCT NAME: COCRISTAL DE TRAMADOL, OPCIONALMENTE EN FORMA DE UNA SAL FISIOLOGICAMENTE ACEPTABLE, Y CELECOXIB; NATIONAL AUTHORISATION NUMBER: 89051; DATE OF AUTHORISATION: 20230925; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 89051; DATE OF FIRST AUTHORISATION IN EEA: 20230925 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
